Benzinga··Vandana SinghBiogen Stock Surges on FDA Nod for High-Dose Spinraza in Rare Muscle Disease
$BIOG rallies as FDA approves high-dose Spinraza for spinal muscular atrophy, while litifilimab shows positive Phase 2 lupus results.
BIIBFDA approvalbiotech